# Glycoprotein IIb/IIIa Inhibitors Versus Standard Therapy in Patients with Myocardial Infarction and No-reflow

> **NCT02739711** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **University of Luebeck** · enrollment: 120 (estimated)

## Conditions studied

- Acute Myocardial Infarction

## Interventions

- **DRUG:** Glycoprotein IIb/IIIa inhibitors

## Key facts

- **NCT ID:** NCT02739711
- **Lead sponsor:** University of Luebeck
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-07
- **Primary completion:** 2024-05
- **Final completion:** 2025-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02739711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02739711, "Glycoprotein IIb/IIIa Inhibitors Versus Standard Therapy in Patients with Myocardial Infarction and No-reflow". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02739711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*